Statistical summary and analysis methods
| Figure reported | N | Normal distribution | Statistic | Statistic value (df) | p value | Variance source | Post hoc test | Post hoc p |
|---|---|---|---|---|---|---|---|---|
| 1A, PD vs control | 5 | Yes | Unpaired t test | t(8) = 2.644 | 0.0295 | Difference | ||
| 1B, PD vs control | 5 | Yes | Unpaired t test | t(8) = 3.418 | 0.0091 | Difference | ||
| 1C, PD vs control | 5 | Yes | Unpaired t test | t(8) = 2.449 | 0.0400 | Difference | ||
| 2A | 3 | Yes | One-way ANOVA | F(3,8) = 41.01 | <0.0001 | Treatment | ||
| 2A, PBS vs LPS | 3 | Yes | Tukey | 0.0025 | ||||
| 2A, LPS+inhibitor NC vs LPS+ miR-132-3p inhibitor | 3 | Yes | Tukey | <0.0001 | ||||
| 2B, TNF-α | 3 | Yes | One-way ANOVA | F(3,8) = 62.48 | <0.0001 | Treatment | ||
| 2B, TNF-α, PBS vs LPS | 3 | Yes | Tukey | <0.0001 | ||||
| 2B, TNF-α, LPS+ inhibitor NC vs LPS +miR-132-3p inhibitor | 3 | Yes | Tukey | 0.001 | ||||
| 2B, IL-1β | 3 | Yes | One-way ANOVA | F(3,8) = 68.03 | <0.0001 | Treatment | ||
| 2B, IL-1β, PBS vs LPS | 3 | Yes | Tukey | <0.0001 | ||||
| 2B, IL-1β, LPS+ inhibitor NC vs LPS +miR-132-3p inhibitor | 3 | Yes | Tukey | 0.001 | ||||
| 2B, IL-6 | 3 | Yes | One-way ANOVA | F(3,8) = 55.19 | <0.0001 | Treatment | ||
| 2B, IL-6, PBS vs LPS | 3 | Yes | Tukey | <0.0001 | ||||
| 2B, IL-6, LPS+ inhibitor NC vs LPS +miR-132-3p inhibitor | 3 | Yes | Tukey | 0.005 | ||||
| 2C, TNF-α | 3 | Yes | One-way ANOVA | F(3,8) = 38.98 | <0.0001 | Treatment | ||
| 2C, TNF-α, PBS vs LPS | 3 | Yes | Tukey | <0.0001 | ||||
| 2C, TNF-α, LPS+ inhibitor NC vs LPS +miR-132-3p inhibitor | 3 | Yes | Tukey | 0.0059 | ||||
| 2C, IL-1β | 3 | Yes | One-way ANOVA | F(3,8) = 70.75 | <0.0001 | Treatment | ||
| 2C, IL-1β, PBS vs LPS | 3 | Yes | Tukey | <0.0001 | ||||
| 2C, IL-1β, LPS+ inhibitor NC vs LPS +miR-132-3p inhibitor | 3 | Yes | Tukey | 0.001 | ||||
| 2C, IL-6 | 3 | Yes | One-way ANOVA | F(3,8) = 86.8 | <0.0001 | Treatment | ||
| 2C, IL-6, PBS vs LPS | 3 | Yes | Tukey | <0.0001 | ||||
| 2C, IL-6, LPS+ inhibitor NC vs LPS +miR-132-3p inhibitor | 3 | Yes | Tukey | 0.001 | ||||
| 3A | 3 | Yes | One-way ANOVA | F(2,6) = 343.2 | <0.0001 | Treatment | ||
| 3A, mimic NC vs miR-132-3p mimic | 3 | Yes | Tukey | <0.0001 | ||||
| 3B, TNF-α | 3 | Yes | One-way ANOVA | F(2,6) = 47.96 | 0.0002 | Treatment | ||
| 3B, TNF-α, mimic NC vs miR-132-3p mimic | 3 | Yes | Tukey | 0.0003 | ||||
| 3B, -IL-1β | 3 | Yes | One-way ANOVA | F(2,6) = 51.95 | 0.0002 | Treatment | ||
| 3B-IL-1β, mimic NC vs miR-132-3p mimic | 3 | Yes | Tukey | 0.0003 | ||||
| 3B, IL-6 | 3 | Yes | One-way ANOVA | F(2,6) = 35 | 0.0005 | Treatment | ||
| 3B, IL-6, mimic NC vs miR-132-3p mimic | 3 | Yes | Tukey | 0.0016 | ||||
| 3C, TNF-α | 3 | Yes | One-way ANOVA | F(2,6) = 69.99 | <0.0001 | Treatment | ||
| 3C, TNF-α, mimic NC vs miR-132-3p mimic | 3 | Yes | Tukey | 0.0002 | ||||
| 3C, IL-1β | 3 | Yes | One-way ANOVA | F(2,6) = 188.5 | <0.0001 | Treatment | ||
| 3C, IL-1β, mimic NC vs miR-132-3p mimic | 3 | Yes | Tukey | <0.0001 | ||||
| 3C, IL-6 | 3 | Yes | One-way ANOVA | F(2,6) = 152.1 | <0.0001 | Treatment | ||
| 3C, IL-6, mimic NC vs miR-132-3p mimic | 3 | Yes | Tukey | <0.0001 | ||||
| 4A | 3 | Yes | One-way ANOVA | F(3,8) = 68.62 | <0.0001 | Treatment | ||
| 4A, PBS vs LPS | 3 | Yes | Tukey | <0.0001 | ||||
| 4A, LPS+inhibitor NC vs LPS+ miR-132-3p inhibitor | 3 | Yes | Tukey | 0.0050 | ||||
| 4B | 3 | Yes | One-way ANOVA | F(3,8) = 114.1 | <0.0001 | Treatment | ||
| 4B, PBS vs LPS | 3 | Yes | Tukey | <0.0001 | ||||
| 4B, LPS+inhibitor NC vs LPS+ miR-132-3p inhibitor | 3 | Yes | Tukey | <0.0001 | ||||
| 4C | 3 | Yes | One-way ANOVA | F(2,6) = 9.25 | 0.0147 | Treatment | ||
| 4C, mimic NC vs miR-132-3p mimic | 3 | Yes | Tukey | 0.0461 | ||||
| 4D | 3 | Yes | One-way ANOVA | F(2,6) = 17.59 | 0.0031 | Treatment | ||
| 4D, mimic NC vs miR-132-3p mimic | 3 | Yes | Tukey | 0.0040 | ||||
| 5A | 3 | Yes | One-way ANOVA | F(3,8) = 35.92 | <0.0001 | Treatment | ||
| 5A, inhibitor NC vs miR-132-3p inhibitor | 3 | Yes | Tukey | 0.006 | ||||
| 5A, mimic NC vs miR-132-3p mimic | 3 | Yes | Tukey | 0.0089 | ||||
| 5B | 3 | Yes | One-way ANOVA | F(3,8) = 13.63 | 0.0005 | Treatment | ||
| 5B, inhibitor NC vs miR-132-3p inhibitor | 3 | Yes | Tukey | 0.01 | ||||
| 5B, mimic NC vs miR-132-3p mimic | 3 | Yes | Tukey | 0.0382 | ||||
| 5C, miR-132-3p | 3 | Yes | One-way ANOVA | F(3,8) = 115.1 | <0.0001 | Treatment | ||
| 5C, miR-132-3p, IgG vs Ago2 | 3 | Yes | Tukey | <0.0001 | ||||
| 5C, GLRX | 3 | Yes | One-way ANOVA | F(3,8) = 126.1 | <0.0001 | Treatment | ||
| 5C, GLRX, IgG vs Ago2 | 3 | Yes | Tukey | <0.0001 | ||||
| 5D, PBS vs LPS | 3 | Yes | Two-way ANOVA | F(2,12) = 12.1 | 0.0013 | Interaction | ||
| 5D, PBS vs LPS | 3 | Yes | Two-way ANOVA | F(2,12) = 168.8 | <0.0001 | Main effect | ||
| 5F | 3 | Yes | One-way ANOVA | F(3,8) = 9.623 | 0.0050 | Treatment | ||
| 5F, wt-GLRX+ mimic NC vs wt-GLRX+miR-132-3p mimic | 3 | Yes | Tukey | 0.0044 | ||||
| 6A | 3 | Yes | One-way ANOVA | F(2,6) = 75.16 | <0.0001 | Treatment | ||
| 6A, mimic NC vs miR-132-3p mimic | 3 | Yes | Tukey | 0.002 | ||||
| 6A, miR-132-3p mimic vs miR-132-3p mimic+GLRX | 3 | Yes | Tukey | <0.0001 | ||||
| 6B | 3 | Yes | One-way ANOVA | F(2,6) = 36.68 | 0.0004 | Treatment | ||
| 6B, mimic NC vs miR-132-3p mimic | 3 | Yes | Tukey | 0.0165 | ||||
| 6B, miR-132-3p mimic vs miR-132-3p mimic+GLRX | 3 | Yes | Tukey | 0.004 | ||||
| 6C, TNF-α | 3 | Yes | One-way ANOVA | F(2,6) = 43.7 | 0.0003 | Treatment | ||
| 6C, TNF-α, mimic NC vs miR-132-3p mimic | 3 | Yes | Tukey | 0.0003 | ||||
| 6C, TNF-α, miR-132-3p mimic vs miR-132-3p mimic+GLRX | 3 | Yes | Tukey | 0.001 | ||||
| 6C, IL-1β | 3 | Yes | One-way ANOVA | F(2,6) = 38.76 | 0.0004 | Treatment | ||
| 6C, IL-1β, mimic NC vs miR-132-3p mimic | 3 | Yes | Tukey | 0.0004 | ||||
| 6C, IL-1β, miR-132-3p mimic vs miR-132-3p mimic+GLRX | 3 | Yes | Tukey | 0.002 | ||||
| 6C, IL-6 | 3 | Yes | One-way ANOVA | F(2,6) = 36.31 | 0.0004 | Treatment | ||
| 6C, IL-6, mimic NC vs miR-132-3p mimic | 3 | Yes | Tukey | 0.0013 | ||||
| 6C, IL-6, miR-132-3p mimic vs miR-132-3p mimic+GLRX | 3 | Yes | Tukey | 0.0005 | ||||
| 6D, TNF-α | 3 | Yes | One-way ANOVA | F(2,6) = 49.81 | 0.0002 | Treatment | ||
| 6D, TNF-α, mimic NC vs miR-132-3p mimic | 3 | Yes | Tukey | 0.0002 | ||||
| 6D, TNF-α, miR-132-3p mimic vs miR-132-3p mimic+GLRX | 3 | Yes | Tukey | 0.0011 | ||||
| 6D, IL-1β | 3 | Yes | One-way ANOVA | F(2,6) = 131.6 | <0.0001 | Treatment | ||
| 6D, IL-1β, mimic NC vs miR-132-3p mimic | 3 | Yes | Tukey | <0.0001 | ||||
| 6D, IL-1β, miR-132-3p mimic vs miR-132-3p mimic+GLRX | 3 | Yes | Tukey | <0.0001 | ||||
| 6D, IL-6 | 3 | Yes | One-way ANOVA | F(2,6) = 65.52 | <0.0001 | Treatment | ||
| 6D, IL-6, mimic NC vs miR-132-3p mimic | 3 | Yes | Tukey | 0.0001 | ||||
| 6D, IL-6, miR-132-3p mimic vs miR-132-3p mimic+GLRX | 3 | Yes | Tukey | 0.003 | ||||
| 6E | 3 | Yes | One-way ANOVA | F(2,6) = 8.975 | 0.0157 | Treatment | ||
| 6E, mimic NC vs miR-132-3p mimic | 3 | Yes | Tukey | 0.0199 | ||||
| 6E, miR-132-3p mimic vs miR-132-3p mimic+GLRX | 3 | Yes | Tukey | 0.0312 | ||||
| 6F | 3 | Yes | One-way ANOVA | F(2,6) = 15.91 | 0.004 | Treatment | ||
| 6F, mimic NC vs miR-132-3p mimic | 3 | Yes | Tukey | 0.0047 | ||||
| 6F, miR-132-3p mimic vs miR-132-3p mimic+GLRX | 3 | Yes | Tukey | 0.0103 | ||||
| 7A | 6 | Yes | One-way ANOVA | F(3,20) = 65.02 | <0.0001 | Treatment | ||
| 7A, saline vs MPTP | 6 | Yes | Tukey | <0.0001 | ||||
| 7A, MPTP+ antagomir NC vs MPTP+miR-132-3p antagomir | 6 | Yes | Tukey | 0.001 | ||||
| 7B | 6 | Yes | One-way ANOVA | F(3,20) = 35.37 | <0.0001 | Treatment | ||
| 7B, saline vs MPTP | 6 | Yes | Tukey | <0.0001 | ||||
| 7B, MPTP+ antagomir NC vs MPTP+miR-132-3p antagomir | 6 | Yes | Tukey | 0.001 |